Shanghai, China

Kuangchu Dai

This inventor holds 1 USPTO granted patent. Top assignee: Lexicon Pharmaceuticals, Inc.. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kuangchu Dai. Retrieved from https://idiyas.com/inventor/kuangchu-dai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kuangchu Dai: Innovator in Pharmaceutical Chemistry

Introduction

Kuangchu Dai is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds. His work has led to advancements in drug formulation and synthesis.

Latest Patents

Dai holds a patent for "Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis." This patent outlines methods for preparing solid forms of the compound, including its salts, solvates, and cocrystals.

Career Highlights

Dai is currently employed at Lexicon Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical sector. His expertise in chemical synthesis and formulation has been instrumental in the company's research and development efforts.

Collaborations

Throughout his career, Dai has collaborated with several esteemed colleagues, including Mark S Bednarz and Jeffrey Manning Eckert. These collaborations have fostered a productive environment for innovation and discovery.

Conclusion

Kuangchu Dai's contributions to pharmaceutical chemistry and his innovative patent work exemplify his commitment to advancing the field. His ongoing efforts at Lexicon Pharmaceuticals, Inc. continue to impact drug development positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…